Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28(9):1508–1513. doi: 10.1200/JCO.2009.22.2265.
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Suzuki H, Ueda T, et al. Hormone treatment for prostate cancer: current issues and future directions. Cancer Chemother Pharmacol. 2005;56(Suppl 1):58–63. doi: 10.1007/s00280-005-0100-x.
   PubMedGoogle Scholar
• Xie W, Regan MM, Buyse M, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35(27):3097–3104. doi: 10.1200/JCO.2017.73.9987.
   PubMed Web of Science ®Google Scholar
• Tangen CM, Hussain MHA, Higano CS, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012;188(4):1164–1169. doi: 10.1016/j.juro.2012.06.046.
   PubMed Web of Science ®Google Scholar
• De Bruycker A, Lambert B, Claeys T, et al. Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int. 2017;120(6):815–821. doi: 10.1111/bju.13938.
   PubMed Web of Science ®Google Scholar
• Kinsey EN, Zhang T, Armstrong AJ. Metastatic hormone-sensitive prostate cancer: a review of the current treatment landscape. Cancer J. 2020;26(1):64–75. doi: 10.1097/PPO.0000000000000418.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. Prostate. 2022;82(13):1237–1247. doi: 10.1200/JCO.19.00799.
   PubMedGoogle Scholar
• Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24. doi: 10.1056/NEJMoa1903307.
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131. doi: 10.1056/NEJMoa1903835.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360. doi: 10.1056/NEJMoa1704174.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746. doi: 10.1056/NEJMoa1503747.
   PubMed Web of Science ®Google Scholar
• Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132–1142. doi: 10.1056/NEJMoa2119115.
   PubMed Web of Science ®Google Scholar
• Gu W, Han W, Luo H, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022;23(10):1249–1260. doi: 10.1016/S1470-2045(22)00507-1.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64. doi: 10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616–1622. doi: 10.1200/JCO.22.00193.
   PubMed Web of Science ®Google Scholar
• Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294–2303. doi: 10.1200/JCO.20.03488.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700. doi: 10.1016/S1470-2045(19)30082-8.
   PubMed Web of Science ®Google Scholar
• Hoyle AP, Ali A, James ND, et al. Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer. Eur Urol. 2019;76(6):719–728. doi: 10.1016/j.eururo.2019.08.006.
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-Term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–1087. doi: 10.1200/JCO.2017.75.3657.
   PubMed Web of Science ®Google Scholar
• Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–262. doi: 10.1016/j.eururo.2015.11.005.
   PubMed Web of Science ®Google Scholar
• Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2020;31(3):442. doi: 10.1093/annonc/mdz396.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399(10336):1695–1707. doi: 10.1016/S0140-6736(22)00367-1.
   PubMed Web of Science ®Google Scholar
• Hussain M, Tombal B, Saad F, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol. 2023;41(20):3595–3607. doi: 10.1200/JCO.23.00041.
   PubMed Web of Science ®Google Scholar
• Wallis CJD, Klaassen Z, Bhindi B, et al. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. Eur Urol. 2018;73(6):834–844. doi: 10.1016/j.eururo.2017.10.002.
   PubMed Web of Science ®Google Scholar
• Chen J, Ni Y, Sun G, et al. Comparison of current systemic combination therapies for metastatic hormone-sensitive prostate cancer and selection of candidates for optimal treatment: a systematic review and Bayesian network meta-analysis. Front Oncol. 2020;10:519388. doi: 10.3389/fonc.2020.519388.
   PubMed Web of Science ®Google Scholar
• Marchioni M, Di Nicola M, Primiceri G, et al. New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta-analysis. J Urol. 2020;203(4):751–759. doi: 10.1097/JU.0000000000000636.
   PubMed Web of Science ®Google Scholar
• Sathianathen NJ, Koschel S, Thangasamy IA, et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol. 2020;77(3):365–372. doi: 10.1016/j.eururo.2019.09.004.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gui H, Wang J, et al. Comparative efficacy of combined radiotherapy, systemic therapy, and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a network meta-analysis and systematic review. Front Oncol. 2020;10:567616. doi: 10.3389/fonc.2020.567616.
   PubMed Web of Science ®Google Scholar
• Ferro M, Lucarelli G, Crocetto F, et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. Crit Rev Oncol Hematol. 2021;157:103198. doi: 10.1016/j.critrevonc.2020.103198.
   PubMed Web of Science ®Google Scholar
• Mori K, Mostafaei H, Sari Motlagh R, et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU Int. 2022;129(4):423–433. doi: 10.1111/bju.15507.
   PubMed Web of Science ®Google Scholar
• Roy S, Sayyid R, Saad F, et al. Addition of docetaxel to androgen receptor axis-targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur Urol Oncol. 2022;5(5):494–502. doi: 10.1016/j.euo.2022.06.003.
   PubMed Web of Science ®Google Scholar
• Wenzel M, Wurnschimmel C, Nocera L, et al. Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. Eur Urol Focus. 2022;8(2):399–408. doi: 10.1016/j.euf.2021.04.003.
   PubMedGoogle Scholar
• Menges D, Yebyo HG, Sivec-Muniz S, et al. Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. Eur Urol Oncol. 2022;5(6):605–616. doi: 10.1016/j.euo.2022.04.007.
   PubMed Web of Science ®Google Scholar
• Yanagisawa T, Rajwa P, Thibault C, et al. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur Urol. 2022;82(6):584–598. doi: 10.1016/j.eururo.2022.08.002.
   PubMed Web of Science ®Google Scholar
• Mandel P, Hoeh B, Wenzel M, et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis. Eur Urol Focus. 2023. doi: 10.1016/j.euf.2022.08.007.
   Google Scholar